Categories
Change Password!
Reset Password!
To estimate the fracture risk among postmenopausal females with osteoporosis following discontinuing BP treatment.
Biophosphates (BP) are the first line drug used
to reduce the risk of vertebral, hip, and non-vertebral fractures in
postmenopausal women with osteoporosis. For most postmenopausal womens with
osteoporosis the benifit of BP outweight the risks. Therefore this study
reported the 40% incresed of clinical fractures in womens who took a BP drug
holiday.
To estimate the fracture risk among postmenopausal
females with osteoporosis following discontinuing BP treatment.
A total of 108 postmenopausal females with
osteoporosis who had undergone a “drug holiday” or continued therapy following
first-line BP therapy were selected for analysis. The appearance of new
clinical fractures at the time of follow-up was also investigated. The
associations between BP “drug holiday” and the appearance of clinical fractures
while checking for confounding factors were identified applying the Cox proportional
hazards models. Log-rank tests and Kaplan-Meier curves were used to analyse the
survival without new clinical fractures.
The patients obtained
Risedronate, Ibandronate, Alendronate, and Zoledronic acid. One hundred
sixty-six patients showed 6 to 36 months of follow-up. The rates of new
clinical fractures at follow-up were 16.1% for “drug holiday” group and
11.9%for another group. After full adjustment, the “drug holiday” patients
showed 1.40 hazard ratio of new clinical fractures.
The risk of recently found clinical fractures was 40%
greater among patients who received a Bisphosphonate drug holiday after the
first-line BP therapy.
Osteoporosis International
Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk
M. A. Mignot et al.
Comments (0)